Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
Rhea-AI Summary
Vivani Medical (Nasdaq: VANI) announced full enrollment and successful initial dosing of all 20 participants in SLIM-1, a Phase 1, randomized, active-controlled trial of NPM-139, a miniature, subdermal, ultra long-acting semaglutide implant for chronic weight management.
The four-week trial in GLP-1 naïve, overweight or obese participants in Australia compares low-dose NPM-139 in 10 participants with the starting dose of Wegovy (0.25 mg/week semaglutide injection) in 10 participants, focusing on safety, tolerability, pharmacokinetics and measuring weight change. Dosing of the first 10 participants began on July 29, 2026, ahead of schedule, with the remaining 10 dosed one week later; all insertion procedures were completed without issues. Top-line data are expected in November 2026 and may support a planned Phase 2 dose-ranging trial in 2027. Vivani highlights prior NPM-139 preclinical data showing sustainable 20% weight reduction in animal models and a July 2026 collaboration with Novo Nordisk to evaluate NPM-139 and its NanoPortal implant platform, which is designed for six- to twelve-month drug delivery and rapid reversibility of GLP-1 exposure.
Positive
- SLIM-1 fully enrolled and dosed: 20 GLP-1 naïve participants completed initial dosing in the Phase 1 NPM-139 trial
- Top-line SLIM-1 data expected November 2026 to inform further NPM-139 development
- Preclinical NPM-139 data showed sustainable 20% weight reduction in animal models
- July 2026 Novo Nordisk agreement to evaluate NPM-139 and NanoPortal implant technology
- NanoPortal design targets six- to twelve-month GLP-1 delivery with potential rapid reversibility
Negative
- None.
News Market Reaction – VANI
In the Aug 6 session, VANI declined 1.45%, reflecting a mild negative market reaction. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Clinical trial Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 25 | Clinical trial approval | Positive | -6.6% | Australia ethics approval authorized initiation of the SLIM-1 Phase 1 trial |
| Sep 04 | Clinical trial plans | Positive | +18.1% | Company outlined Phase 1 and Phase 2 development plans for NPM-139 |
| Aug 05 | Preclinical weight-loss data | Positive | +7.1% | NPM-139 preclinical study showed approximately 20% sustained weight loss |
| Mar 13 | Clinical trial milestone | Positive | +1.9% | NPM-115 achieved first implant and full enrollment in LIBERATE-1 |
| Dec 19 | Clinical trial initiation | Positive | -2.5% | Vivani initiated its first-in-human GLP-1 implant trial in Australia |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Among five tag-specific clinical-trial events, three positive announcements aligned with gains and two diverged with declines.
Key Terms
pharmacokinetics medical
subdermal medical
open-label technical
active-controlled technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Dosing of the first participant commenced ahead of schedule and was rapidly followed by initial dosing in all trial participants.
SLIM-1™ trial is a Phase 1, randomized, controlled clinical trial design to characterize the safety, tolerability, and pharmacokinetics of NPM-139 including a Wegovy® (semaglutide injection) group.
Top-line data from the 20-participant trial is expected in November of 2026.
ALAMEDA, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) today announced full enrollment and successful initial dosing of all participants in its SLIM-1™ Phase 1 trial for NPM-139, a miniature, subdermal semaglutide implant being designed to provide six- to twelve-months of continuous drug delivery utilizing our proprietary NanoPortal™ technology. The trial of 20 GLP-1 naïve participants in Australia includes low-doses of NPM-139 and Wegovy® to assess safety, tolerability, and pharmacokinetics. Changes in weight will be measured.
“Dosing of the first 10 participants occurred on July 29, ahead of schedule. The remaining 10 participants were dosed one week later. All insertion procedures were completed successfully without any issues. Expeditious full enrollment of SLIM-1 trial participants highlights our commitment to rapidly advance the development of our innovative GLP-1 product candidates in chronic weight management and type 2 diabetes,” said Adam Mendelsohn, Ph.D., CEO of Vivani Medical. “We look forward to sharing top-line SLIM-1 clinical data later this year which we anticipate will pave the way for initiation of a Phase 2 dose-ranging trial in 2027.”
This milestone follows NPM-139 preclinical studies demonstrating sustainable
In addition to NPM-139’s primary aim to improve convenience, medication adherence and tolerability, NanoPortal implants are uniquely designed to enable infrequent administration (six months or longer) and the ability to rapidly reverse GLP-1 drug exposure when cessation of therapy is needed or desired. Reversibility can be an important clinical consideration in certain situations, including when a woman becomes pregnant or when patients undergoing surgery have an increased aspiration risk.
About SLIM-1
SLIM-1 is an open-label, active-controlled trial evaluating a low-dose NPM-139 (semaglutide implant) given to 10 participants, and the starting dose of Wegovy (0.25mg/week semaglutide injection) also given to 10 participants, over a four-week duration. The trial is designed to evaluate the safety, tolerability and pharmacokinetic profile in overweight or obese participants who are otherwise healthy. Top-line results from SLIM-1 are expected to be available in November.
About Vivani Medical, Inc.
Leveraging its proprietary NanoPortal™ platform, Vivani develops miniature, biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. These NanoPortal implants are designed for once- or twice-yearly administration to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately
Forward-Looking Statements
This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that are used in this press release, including statements regarding Vivani’s business, products in development, including the therapeutic potential thereof, the planned development thereof, and its technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani’s control. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including, without limitation, risks of unexpected costs or delays, and risks and uncertainties associated with the development and commercialization of products and product candidates that may impact or alter anticipated business plans, strategies and objectives. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Vivani’s expectations in any forward-looking statement. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties are more fully described in periodic filings with the U.S. Securities and Exchange Commission (the “SEC”) including the factors described in Vivani’s most recent Quarterly Report on Form 10-Q filed with the SEC on May 13, 2026, as updated by future filings with the SEC. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law.
Company Contact:
Donald Dwyer
Chief Business Officer
info@vivani.com
(415) 506-8462
Investor and Media Relations Contact:
Jami Taylor
Investor and Media Relations Advisor
investors@vivani.com
(415) 506-8462
